-+ 0.00%
-+ 0.00%
-+ 0.00%

ABBVIE: LUTIKIZUMAB WAS GENERALLY WELL TOLERATED, WITH NO NEW SAFETY CONCERNS IDENTIFIED

Reuters·10/22/2026 13:00:00

Please log in to view news